Contact Us

LHA Investor Relations
212 838 3777
kgolodetz@lhai.com

Stock Quote
NASDAQSRTS

Investor Relations

Sensus Healthcare, Inc. (NASDAQ: SRTS; SRTSW) is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients.

Letter to Stockholders

Sensus Fact Sheet

Contact Us

LHA Investor Relations
212 838 3777
kgolodetz@lhai.com

Recent News
Oct 11, 2017

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radiation Therapy (SRT), today announced...

Oct 9, 2017

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radiation Therapy (SRT), announced today...

Oct 9, 2017

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radiation Therapy (SRT), announces that at...

Read More>